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The global diversity of HIV-1 represents a critical chal-
lenge facing HIV-1 vaccine development. HIV-1
mosaic antigens are bioinformatically optimized im-
munogens designed for improved coverage of HIV-1
diversity. However, the protective efficacy of such
global HIV-1 vaccine antigens has not previously
been evaluated. Here, we demonstrate the capacity
of bivalent HIV-1 mosaic antigens to protect rhesus
monkeys against acquisition of infection following
heterologous challenges with the difficult-to-neu-
tralize simian-human immunodeficiency virus SHIV-
SF162P3. Adenovirus/poxvirus and adenovirus/
adenovirus vector-based vaccines expressing HIV-1
mosaicEnv,Gag, andPol affordedasignificant reduc-
tion in the per-exposure acquisition risk following re-
petitive, intrarectal SHIV-SF162P3challenges.Protec-
tion against acquisition of infection correlated with
vaccine-elicited binding, neutralizing, and functional
nonneutralizing antibodies, suggesting that the coor-
dinated activity of multiple antibody functions may
contribute to protection against difficult-to-neutralize
viruses. These data demonstrate the protective effi-
cacy ofHIV-1mosaic antigens and suggest a potential
strategy for thedevelopmentofaglobalHIV-1vaccine.INTRODUCTION
The extraordinary degree of HIV-1 sequence diversity worldwide
represents one of the most daunting challenges for the develop-ment of a global HIV-1 vaccine (Barouch, 2008; Gaschen et al.,
2002; Walker and Korber, 2001). The development of a vaccine
that is immunologically relevant for multiple regions of the world
is therefore a key research priority (Stephenson and Barouch,
2013). One possible solution would be to develop a different
HIV-1 vaccine for each geographic region that is tailored to local
circulating isolates. However, a single global vaccine would offer
important biomedical and practical advantages over multiple
regional clade-specific vaccines.
Mosaic antigens (Fischer et al., 2007) and conserved antigens
(Le´tourneau et al., 2007; Stephenson et al., 2012b) represent two
potential strategies to address the challenges of global HIV-1
diversity. Mosaic antigens aim to elicit increased breadth of
humoral and cellular immune responses for improved immuno-
logic coverage of diverse sequences, whereas conserved anti-
gens aim to focus cellular immune responses on regions of
greatest sequence conservation. Immunogenicity studies in
nonhuman primates have shown that mosaic antigens elicit
increased cellular immune breadth and depth (Barouch et al.,
2010; Santra et al., 2010), as well as augmented antibody re-
sponses (Barouch et al., 2010; Stephenson et al., 2012b), as
compared with natural sequence and consensus antigens. How-
ever, no previous studies have assessed the protective efficacy
of these global HIV-1 antigen concepts, and it has been unclear
whether the immune responses elicited by in silico derived syn-
thetic antigens will exert biologically relevant antiviral activity.
This question is of particular importance given the current plans
for clinical development of these mosaic antigens.
It has also proven challenging to evaluate the preclinical effi-
cacy of HIV-1 immunogens that do not have SIV homologs.
This is relevant for HIV-1 mosaic antigens because HIV-1
sequence diversity in humans is biologically substantially
different from SIV sequence diversity in sooty mangabees.
Moreover, SIV in natural hosts exhibits markedly decreasedCell 155, 531–539, October 24, 2013 ª2013 Elsevier Inc. 531
positive selection as compared with HIV-1 in humans, presum-
ably as a result of the lower level of immune selection pressure
and a much longer evolutionary history (Fischer et al., 2012). In
addition, only limited numbers of SIV sequences are available
to inform mosaic vaccine design (Fischer et al., 2012). It is
currently not possible to develop SIV homologs of mosaic anti-
gens that accurately recapitulate the biology of HIV-1 mosaic
antigens, and we therefore opted not to assess the protective
efficacy of SIV homologs of mosaic antigens in SIV challenge
models. Instead, we evaluated the capacity of HIV-1 mosaic
antigens to protect against stringent simian-human immunodefi-
ciency virus (SHIV) challenges in rhesus monkeys.
In this study,weassessed the immunogenicityof bivalentHIV-1
mosaic Env/Gag/Pol immunogens (Barouch et al., 2010) deliv-
ered by optimized Ad/MVA or Ad/Ad prime-boost vector regi-
mens (Barouch et al., 2012), and we evaluated the protective
efficacy of these vaccines against repetitive, intrarectal chal-
lenges with the stringent, difficult-to-neutralize, heterologous
virusSHIV-SF162P3 in rhesusmonkeys.BecauseSHIVs incorpo-
rate HIV-1 Env and SIV Gag/Pol (Reimann et al., 1996a, 1996b),
this study primarily evaluated the ability of the HIV-1 Env compo-
nents of these vaccines to block acquisition of infection. To the
best of our knowledge, this study represents the first evaluation
of the protective efficacy of a candidate global HIV-1 antigen
strategy in nonhuman primates. We demonstrate that binding,
neutralizing, and nonneutralizing antibody responses correlate
with protection, suggesting that the coordinated activity of multi-
ple antibody functions may contribute to protective efficacy.
RESULTS
Evaluation of a Global HIV-1 Mosaic Vaccine in Rhesus
Monkeys
We immunized 36 Indian-origin rhesus monkeys (Macaca mu-
latta) that did not express the class I alleles associated with
spontaneous virologic control (Mamu-A*01, Mamu-B*08, and
Mamu-B*17) (Loffredo et al., 2007; Mothe´ et al., 2003; Yant
et al., 2006) with Ad prime, MVA boost (Group 1; n = 12) or Ad
prime, Ad boost (Group 2; n = 12) vector regimens expressing
bivalent M mosaic Env/Gag/Pol immunogens or with sham vac-
cines (Group 3; n = 12). In Group 1, half the animals received the
Ad26 prime, MVA boost regimen, and half received the Ad35
prime, MVA boost regimen. In Group 2, half the animals received
the Ad26 prime, Ad35 boost regimen, and half received the Ad35
prime, Ad26 boost regimen. One animal in Group 1 died for rea-
sons unrelated to the study prior to the boost immunization and
thus was excluded from the analysis. Groups were balanced for
animals with susceptible and resistant TRIM5a alleles (Letvin
et al., 2011; Lim et al., 2010). The Ad vectors expressing HIV-1
mosaic Env/Gag/Pol have been described previously (Barouch
et al., 2010). The MVA vectors were constructed by inserting
the HIV-1 mosaic Env and Gag/Pol expression cassettes into
two distinct regions of the MVA backbone (Earl et al., 2004)
(L.A.E., P.L.E., and B.M., unpublished data). At week 0, monkeys
were primed by the intramuscular (i.m.) route with a total dose of
4 3 1010 viral particles (vp) Ad26 or Ad35 vectors. At week 12,
animals were boosted i.m. with 43 1010 vp Ad26 or Ad35 vectors
or 108 pfu MVA vectors.532 Cell 155, 531–539, October 24, 2013 ª2013 Elsevier Inc.Binding, Neutralizing, and Nonneutralizing Antibody
Responses
Binding antibody responses were detected in all vaccinated
animals by ELISA (Nkolola et al., 2010) at week 4 after the priming
immunization and increased substantially following the boost
immunization (Figure 1A). Binding antibodies withmean log titers
of 3.3–4.9 were detected at week 16 against diverse Envs from
multiple clades (Barouch et al., 2010) (92UG037, UG92/29,
CN54, ZA/97/003, 92UG021, 93BR029), as well as against one
of the homologous mosaic Envs (Mos1) included in the vaccine.
Antibody titers declined 1 to 2 logs from peak to mean log titers
of 2.0–3.0 by week 32, and titers were then stable through week
52 (data not shown). Antibody responses against the Env V2 loop
(Haynes et al., 2012) were also detected against multiple clades
(92TH023, B_MN, ConC, Mos1, Mos2) using surface plasmon
resonance assays with cyclic peptides (Figure 1B) and gp70-
V1V2 fusion proteins (data not shown). No significant immuno-
logic differences were observed among the different vector
regimens.
Neutralizing antibodies (NAbs) against easy-to-neutralize tier 1
viruses were detected by TZM-bl virus neutralization assays
(Montefiori, 2004). Mean titers of 69–153 were detected at
week 16 against SF162 (clade B) and MW965 (clade C), and
low mean titers of 21–31 were observed against DJ263
(clade A) (Figure 1C). Low but clear mean titers of 37–99 were
also detected against 3 of 4 difficult-to-neutralize tier 2 viruses
by A3R5 assays, including SC22 (clade B), 1086 (clade C), and
DU422 (clade C) (Figure 1D). Moreover, low NAb titers were
observed against the difficult-to-neutralize tier 2 SHIV-
SF162P3 challenge virus by TZM-bl assays (Figure 1E).
Nonneutralizing functional antibody-dependent complement
deposition (ADCD) (Figure 1F) and antibody-dependent cellular
phagocytosis (ADCP) (Figure 1G) (Ackerman et al., 2011)
responses were also observed at week 16. ADCD assays evalu-
ated antibody-mediated C3b deposition on Env-pulsed CEM
target cells, and ADCP assays assessed antibody-mediated
phagocytosis of Env-pulsed fluorescent beads by THP-1 cells.
Low levels of antibody-dependent cellular cytotoxicity (ADCC)
were also detected (data not shown) (Go´mez-Roma´n et al.,
2006). These data demonstrate that the Ad/MVA and Ad/Ad
regimens expressing the mosaic Env immunogens elicited a
diversity of binding, neutralizing, and nonneutralizing antibody
responses.
Breadth and Depth of Cellular Immune Responses
Robust cellular immune responses against HIV-1 Env, Gag, and
Pol were detected by IFN-g ELISPOT assays (Liu et al., 2009).
The magnitude and breadth of cellular immune responses (Fig-
ures 2A and 2B) were comparable for the various vector regi-
mens tested and were similar to our previously reported findings
(Barouch et al., 2010; Stephenson et al., 2012b). Detailed
epitopemappingwas performed using both homologousmosaic
and heterologous global potential T cell epitope (PTE) peptides,
and the minimal number of epitope-specific responses was
determined for each animal (Table S1 available online). There
were significantly more CD8+ than CD4+ T lymphocyte re-
sponses per animal (p = 0.0006, Wilcoxon rank-sum test) (Fig-
ures 2C and 2D). Most epitope-specific responses were
Figure 1. Vaccine-Elicited Humoral Immune Responses
(A) Env-specific ELISAs using a diversity of Envs frommultiple clades, including 92UG037 (UG37; clade A), UG92/29 (UG92; clade A), CN54 (clade C), ZA/97/003
(ZA97; clade C), 92UG021 (UG21; clade D), 93BR029 (BR29; clade F), and mosaic (Mos1; clade M) at weeks 0, 4, 16, and 32. Mean log endpoint ELISA titers ±
SEM are shown.
(B) V2-specific binding assays by surface plasmon resonance using cyclic V2 peptides from multiple clades, including 92TH023 (TH23; clade AE), MN (clade B),
ConC (clade C), Mos1 (clade M), andMos2 (clade M) at weeks 0, 4, 16, and 24. V2-specific binding assays were not run with the TH23 andMN cyclic V2 peptides
at week 24. Mean response units ± SEM are shown.
(C) HIV-1 tier 1 TZM-bl neutralization assays against DJ263 (clade A), SF162 (clade B), andMW965 (clade C) at weeks 0, 4, 16, and 32.Mean ID50 titers ±SEMare
shown.
(D) HIV-1 tier 2 A3R5 neutralization assays against SC22 (clade B), 1086 (clade C), and DU422 (clade C) at weeks 0 and 16. Mean ID50 titers ± SEM are shown.
(E) HIV-1 tier 2 TZM-bl neutralization assays against the SHIV-SF162P3 challenge stock at weeks 0, 16, and 32. Mean ID50 titers are shown.
(F) ADCD assays with YU2 (clade B) and SF162 (clade B) Env gp120. Mean % C3b deposition responses ± SEM are shown.
(G) ADCP assays with SF162 (clade B) Env gp120. Mean phagocytic score responses ± SEM are shown.
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Figure 2. Vaccine-Elicited Cellular Immune Responses
(A) IFN-g ELISPOT assays using global PTE peptide pools at weeks 0, 4, and 16. Mean spot-forming cells (SFC) per 106 PBMC ± SEM are shown.
(B) Numbers of reactive subpools of 10–16 peptides using PTE and mosaic peptide sets. Mean subpools ± SEM are shown.
(C) Numbers of mapped individual CD8+ and CD4+ T lymphocyte epitopes. Mean epitopes ± SEM are shown.
(D) Individual CD8+ and CD4+ epitope-specific immune responses mapped with heterologous PTE and vaccine-matched mosaic peptide sets. 83 responses
were detected by both PTE and mosaic peptides, 58 by only mosaic peptides, and 27 by only PTE peptides. Box-and-whisker plots are shown.
See also Figure S1, Table S1, and Data S2.detected using both peptide sets, but certain epitopes were
detected uniquely with either the mosaic peptides or the PTE
peptides (Figure 2D). Individual epitope-specific CD8+ and
CD4+ T lymphocyte responses showed substantial animal-to-
animal variability (Figure S1) but nevertheless appeared to
cluster in immunologic hot spots (Data S1), despite the outbred
nature of the monkeys.
Protective Efficacy, Immunologic Correlates of
Protection, and Clinical Disease
To assess the protective efficacy of the vaccines, we challenged
all animals beginning at week 52 (9 months following the boost
immunization) 6 times with a 1:100 dilution of our SHIV-
SF162P3 challenge stock (GenBank KF042063; Data S2). The
SHIV-SF162P3 Env had 13% amino acid sequence differences
compared with Mos1 Env from the vaccine and 26% amino
acid sequence differences compared with Mos2 Env. After the
first challenge, 8 of 11 (73%) Ad/MVA and 8 of 12 (67%) Ad/Ad
vaccinated animals remained uninfected as compared with
only 2 of 12 (17%) controls (Figures 3A and 3B; p = 0.03, Fisher’s
exact test). After the third challenge, 5 of 11 (45%) Ad/MVA and 5534 Cell 155, 531–539, October 24, 2013 ª2013 Elsevier Inc.of 12 (42%) Ad/Ad vaccinated animals remained uninfected as
compared with 0 of 12 (0%) controls (Figures 3A and 3B; p =
0.03, Fisher’s exact test). As expected, absolute protection
declined with additional challenges, and after the sixth and final
challenge, only 2 of 11 (18%) Ad/MVA and 1 of 12 (8%) Ad/Ad
vaccinated animals remained uninfected. These data reflected
a 90% (p = 0.002, Cox proportional hazard model using the
number of challenges as a discrete time scale) and 87% (p =
0.007) reduction, respectively, in the per-exposure relative risk
of acquisition of infection (Figures 3A and 3B) (Hudgens and
Gilbert, 2009; Hudgens et al., 2009). Thus, the mosaic HIV-1
vaccines afforded partial protection against acquisition of infec-
tion following repetitive, intrarectal, heterologous SHIV-SF162P3
challenges. No differences in protective efficacy were observed
between Ad26 versus Ad35 priming in each group (data not
shown).
We next evaluated the immunologic correlates of protection
against acquisition of infection in the vaccinated animals,
defined as the number of challenges required for infection. We
assessed 47 humoral and cellular immunologic parameters
for potential correlation with protection (Table S2). Three
Figure 3. Protective Efficacy against SHIV-
SF162P3 Challenges
(A) Number of challenges required for acquisition
of infection in each vaccine group.
(B) Statistical analyses include hazard ratios with
95% confidence intervals (CI), the per-exposure
reduction in acquisition risk, and the absolute
percentage of uninfected animals in each group
after 1, 3, and 6 challenges. p values reflect Cox
proportional hazard model.
(C) Log peak SIV RNA copies/ml are depicted for
each group. p values represent Wilcoxon rank-
sum tests. Box-and-whisker plots are shown.
(D) Log set point SIV RNA copies/ml are depicted
for each group at day 70. Box-and-whisker plots
are shown.
(E) Clinical survival curve.
(F) Statistical analyses of survival at 250 days
following challenge. p values reflect Fisher’s exact
tests comparing the vaccinated groups to the
control group.parameters were significantly associated with protection after
Bonferroni multiple comparison adjustments. Protection was
most strongly correlated with week 16 ELISA binding antibody ti-
ters against the homologous Mos1 Env immunogen (p = 1.2 3
107, Spearman rank-correlation test; Figure 4A). Protection
was also correlated with ELISA binding antibody titers against
other Env immunogens, although these associations were less
robust (Table S2 and Figure S2). In addition, protection was sig-
nificantly correlated with NAb titers against SF162 (p = 7.2 3
104; Figure 4B), which is a neutralization-sensitive virus that is
related to the challenge virus SHIV-SF162P3. NAb titers against
other tier 1 viruses also showed trends toward correlation with
protection (Table S2 and Figure S3). In addition, protection
was correlated with functional nonneutralizing ADCP phagocytic
score (p = 3.03 104; Figure 4C), and a trend was observed with
ADCD C3b complement deposition (Figure 4D). We did not,
however, observe significant correlations of protection with
surface plasmon resonance binding to cyclic V2 peptides orCell 155, 531–539,gp70-V1V2 fusion proteins or any mea-
sure of CD8+ T lymphocyte responses.
Peak viral loads weremodestly lower in
the vaccinated animals as compared with
the controls. Median peak viral loads
in the Ad/MVA and Ad/Ad vaccinated
monkeys were 0.50 (p = 0.048, Wilcoxon
rank-sum test) and 0.55 (p = 0.017) logs
lower, respectively, than in the controls
(Figure 3C). Set point viral loads trended
1.14 and 0.55 logs lower in the vaccine
groups, respectively, than in the controls
(Figure 3D). The HIV-1 mosaic Gag and
Pol immunogens in the vaccine had no
detectable immunologic cross-reactivity
with SIVmac239 Gag and Pol in the chal-
lenge virus by pooled peptide IFN-g
ELISPOT assays (data not shown). Thus,
the modest virologic control likely re-flected Env-specific immune responses, although themagnitude
and breadth of Env-specific T lymphocyte responses were not
significantly correlated with virologic control (Table S2). This is
consistent with our previous observations that virologic control
following challenge is primarily mediated byGag-specific cellular
immune responses (Stephenson et al., 2012a), and thus it is not
surprising that the observed virologic control was only modest in
this study. In contrast, similar Ad/MVA and Ad/Ad vector regi-
mens expressing SIVsmE543 antigens afforded >2 log reduc-
tions of set point viral loads following heterologous SIVmac251
challenges in a prior study (Barouch et al., 2012).
We observed substantial clinical disease progression and
AIDS-related mortality in the controls. At 250 days following
challenge, all of the vaccinated animals survived, as compared
with only 7 of 12 (58%) of controls (Figures 3E and 3F; p =
0.03, Fisher’s exact test). These data confirm the stringency of
our SHIV-SF162P3 challenge stock and demonstrate a survival
advantage of the HIV-1 mosaic vaccines in this model.October 24, 2013 ª2013 Elsevier Inc. 535
Figure 4. Immunologic Correlates of Pro-
tection
(A) Correlation of log Mos1 ELISA titers at peak
immunogenicity with the number of challenges
required to establish infection.
(B) Correlation of log SF162 NAb titers at peak
immunogenicity with the number of challenges
required to establish infection.
(C) Correlation of SF162 ADCP phagocytic score
at peak immunogenicity with the number of chal-
lenges required to establish infection.
(D) Correlation of SF162 ADCD % C3b deposition
at peak immunogenicity with the number of chal-
lenges required to establish infection.
For all panels, correlates analyses included only
the vaccinatedmonkeys that became infected and
did not include the sham controls. p values reflect
uncorrected Spearman rank-correlation tests.
See also Figures S2 and S3 and Table S2.DISCUSSION
This study demonstrates the protective efficacy of a global HIV-1
vaccine candidate in nonhuman primates. In particular, bivalent
mosaic HIV-1 Env/Gag/Pol delivered by Ad/MVA or Ad/Ad vec-
tor regimens afforded substantial partial protection against
repetitive, intrarectal, heterologous SHIV-SF162P3 challenges
in rhesus monkeys. Although most vaccinated animals became
infected by the end of the challenge series, we observed 87%–
90% reduction in the per-exposure probability of infection.
This protective effect was likely mediated by Env-specific
immune responses because the challenge virus contained
SIVmac239 Gag/Pol. These findings suggest that HIV-1 mosaic
vaccine candidates should be evaluated in clinical trials.
The majority of HIV-1 vaccine candidates have to date only
demonstrated protective efficacy against low stringency,
easy-to-neutralize virus challenges. For example, DNA/Ad5
vaccines afforded partial protection against acquisition of the
easy-to-neutralize virus SIVsmE660 but failed to protect against
the difficult-to-neutralize virus SIVmac251 (Letvin et al., 2011).
Moreover, HIV-1 Env vaccines have typically only been tested
for protective efficacy against easy-to-neutralize viruses, such
as SHIV-SF162P4 or SHIV-BaL (Barnett et al., 2008, 2010),
rather than against the difficult-to-neutralize virus SHIV-
SF162P3. The recent failure of the DNA/Ad5 vaccine in humans
suggests that preclinical evaluations of HIV-1 vaccine candi-
dates should involve difficult-to-neutralize challenge models
with higher stringency. The protection observed in the present
study is therefore notable in that SHIV-SF162P3 exhibits a tier
2 difficult-to-neutralize phenotype that is typical of a primary
virus isolate (Seaman et al., 2010). Moreover, SHIV-SF162P3
resulted in moderate to high viral loads and substantial clinical
disease progression and AIDS-related mortality in the controls
(Figure 3).536 Cell 155, 531–539, October 24, 2013 ª2013 Elsevier Inc.Importance of Vaccine-Elicited
Antibody Responses
Consistent with previous data in the SIV-
mac251 challenge model (Barouch et al.,2012), we observed that Env-specific binding antibodies corre-
lated most strongly with protection. Binding antibodies were
detected as immune correlates in the RV144 clinical vaccine trial
(Haynes et al., 2012; Rerks-Ngarm et al., 2009), although we did
not detect V2-specific correlates for protection in the present
study, perhaps reflecting different vaccine vectors, challenge
viruses, or V2 scaffolds utilized in the immunologic assays.
Vaccine-elicited NAbs against SF162 also correlated with
protection, and low levels of NAbs were detected against the
heterologous, difficult-to-neutralize SHIV-SF162P3 challenge vi-
rus. In addition, nonneutralizing ADCP responses also correlated
with protection. These data demonstrate that immunologic cor-
relates of protection were complex and involved multiple vac-
cine-elicited binding, neutralizing, and nonneutralizing antibody
responses. It is therefore possible, in the absence of high titers
of broadly neutralizing antibodies, that the coordinated activity
of multiple antibody functions may contribute to affording pro-
tection against difficult-to-neutralize viruses. The mosaic Env
immunogens also elicited broad Env-specific CD4+ T lympho-
cyte responses that may have facilitated the induction and dura-
bility of antibody responses.
Implications for HIV-1 Vaccine Development
Mosaic antigens represent a potential strategy to improve hu-
moral and cellular immunologic coverage of global HIV-1 diver-
sity as compared with conventional natural sequence antigens,
and they are therefore promising for HIV-1 vaccine development.
Mosaic antigens may also offer a practical strategy for achieving
comparable immunologic coverage utilizing fewer vaccine anti-
gens than would be required with cocktails of natural sequence
antigens. Clinical evaluation of the bivalent HIV-1 mosaic anti-
gens in humans is therefore planned.
The present findings demonstrate that the immune responses
elicited by these synthetic antigens can afford protection in vivo.
Moreover, the correlation of multiple antibody parameters with
protection suggests that both neutralizing and nonneutralizing
antibodies may contribute to protection. A limitation of the pre-
sent study, however, is that we were only able to evaluate pro-
tective efficacy against a single clade B challenge virus. Ideally,
global HIV-1 antigens should be assessed for protective efficacy
against a panel of diverse SHIVs. However, SHIV challenge
stocks from multiple clades do not yet exist, with the exception
of a limited number of clade C SHIVs (Ren et al., 2013; Siddappa
et al., 2010, 2011). Thus, future studies could evaluate the
protective efficacy of global HIV-1 mosaic antigens against a
diversity of virus isolates after additional SHIV challenge stocks
are developed.
The clinical implications of our data remain unknown and will
require efficacy trials in humans. However, it is worth noting
that the viral challenge in the present study was 100-fold
more infectious than typical sexual HIV-1 exposures in humans.
Moreover, future studies are planned utilizing purified recombi-
nant Env trimers to boost the antibody responses elicited by
these HIV-1 mosaic vector regimens. In summary, this study
demonstrates the initial proof-of-concept protective efficacy of
synthetic HIV-1 mosaic antigens in rhesus monkeys and pro-
vides important insights into the correlates of protection against
stringent virus challenges.
EXPERIMENTAL PROCEDURES
Animals, Immunizations, and Challenges
36 Indian-origin, outbred, youngadult,male and female, specificpathogen-free
(SPF) rhesus monkeys (Macaca mulatta) that did not express the class I alleles
Mamu-A*01,Mamu-B*08, andMamu-B*17 associated with spontaneous viro-
logic control (Loffredo et al., 2007;Mothe´ et al., 2003; Yant et al., 2006)were uti-
lized for this study.Groupswere balanced for susceptible and resistant TRIM5a
alleles (see also Table S3) (Letvin et al., 2011; Lim et al., 2010). Immunizations
were performed by the i.m. route in the quadriceps muscles with 4 3 1010 vp
Ad35 vectors (Vogels et al., 2003), 4 3 1010 vp Ad26 vectors (Abbink et al.,
2007), or 108 pfu MVA vectors expressing bivalent M mosaic Env/Gag/Pol
antigens (Barouch et al., 2010). Monkeys were primed at week 0 and boosted
at week 12. To evaluate for protective efficacy, all monkeys were challenged
repetitively beginning at week 52 with six intrarectal inoculations of the heterol-
ogous virus SHIV-SF162P3 utilizing a 1:100dilution of our challenge stock. This
virus stock was produced by expansion of the NIAID SHIV-SF162P3 stock in
rhesus peripheral blood mononuclear cells (PBMC) followed by titration by
the intrarectal route in rhesus monkeys and full genome sequencing (see also
Data S2). Following challenge, monkeys were bled weekly for viral loads
(Siemans Diagnostics), and the date of infection was defined as the last chal-
lenge time point prior to the first positive SIV RNA level. Animals were followed
to determine set point viral loads. All animal studies were approved by the
appropriate Institutional Animal Care and Use Committee (IACUC).
Humoral Immune Assays
ELISA
HIV-1-specific humoral immune responses were assessed by Env ELISAs
(Nkolola et al., 2010) using antigens produced in stably transfected 293 cells
or commercially purchased (Polymun). V2 binding assays were performed
by surface plasmon resonancewith a Biacore T100 or T200 using a 1:50 serum
dilution and cyclic V2 peptides containing an N-terminal biotin tag and immo-
bilized on streptavidin-coated CM5 chips (Barouch et al., 2012) or using gp70-
V1V2 fusion proteins.
NAb Assays
TZM-bl luciferase-based virus neutralization assays (Montefiori, 2004) were
performed with tier 1 viruses and the tier 2 SHIV-SF162P3 challenge stock.
A3R5 virus neutralization assays were conducted with tier 2 viruses.ADCP
Functional nonneutralizing antibody responses utilized IgG purified from
serum using Melon Gel columns (Thermo Scientific) and quantitated using a
Nanodrop spectrophotometer (Thermo Scientific). ADCP assays were per-
formed as previously described (Ackerman et al., 2011). SF162 gp120
biotinylated antigen was incubated with 1 mmyellow-green fluorescent neutra-
vidin beads (Invitrogen) overnight. The beads were then washed and resus-
pended at a final dilution of 1:100 in PBS-BSA. Antibodies and 9 3 105
antigen-labeled beads were mixed in a round-bottom 96-well plate, and the
plate was incubated for 2 hr. THP-1 cells (2 3 104 cells) were then added to
each well in a final volume of 200 ml, and the plate was incubated overnight.
The next day, half the culture volume was removed and replaced with 100 ml
of 4% paraformaldehyde before the plates were analyzed on a BD LSR II
equipped with an HTS plate reader. For analysis, the samples were gated on
live cells, and the proportion of THP-1 cells phagocytosing beads was deter-
mined. A phagocytic score was calculated as follows: % bead positive 3MFI
bead positive.
Rapid Fluorometric ADCC
The rapid fluorometric ADCC (RF-ADCC) assay was performed as previously
described (Go´mez-Roma´n et al., 2006). Briefly, 1 3 106 CEM.NKr cells
(AIDS Reagent Program) were pulsed with 6 mg of recombinant SF162
gp120 for 1 hr and then washed twice in cold media. Uncoated CEM.NKr cells
were used as a negative control. Both the coated and uncoated target cells
were stained with 1.5 mM PKH26 (Sigma) and 100 nM 5-(and-6)-carboxyfluor-
escein diacetate, succinimidyl ester (CFSE). After staining, the cells were re-
suspended at a concentration of 4 3 105 cells/ml, and 2 3 104 cells were
added to each well. Purified antibodies were added (50 mg/ml), and the plates
were incubated for 20 min at 37C and 5% CO2 to allow the binding of the
antibodies to the target cell. Natural killer (NK) cells were isolated directly
from healthy donor whole blood by negative selection using RosetteSep
(Stem Cell Technologies) and added to each well at an effector:target ratio
10:1. The plates were then incubated for 4 hr at 37C, after which the cells
were fixed in 2% paraformaldehyde. ADCC activity was determined using
flow cytometry and was based on the loss of CFSE on PKH+ CEM.NKr cells.
The data were analyzed using FlowJo software, and the percentage of CFSE
loss within the PKH+ CEM.NKr population was determined.
ADCD
ADCD was determined by C3b deposition on gp120-pulsed target cells.
Briefly, 1 3 106 CEM.NKr cells were pulsed with 6 mg of recombinant gp120
(YU-2 or SF162) for 1 hr at room temperature and then washed twice in cold
media. Uncoated CEM.NKr cells were used as a negative control. Plasma
was utilized as a source of complement for the assay. 25 mg purified antibodies
were added to 105 CEM.NKr cells in the presence of plasma diluted 1:10 in
veronal buffer supplemented with 0.1% gelatin for 20 min at 37. Cells were
washed and stained with a FITC-conjugated C3b antibody for 15min, washed,
and fixed in 4% PFA. HIVIG was used a positive control for this assay, and
heat-inactivated plasma and antibodies from naive controls were utilized as
negative controls.
Cellular Immune Assays
HIV-1-specific cellular immune responses were assessed by IFN-g ELISPOT
assays as previously described (Liu et al., 2009). ELISPOT assays utilized
pools of HIV-1 PTE or mosaic peptides. Analyses of cellular immune breadth
utilized subpools of 10–16 peptides covering each antigen followed by epitope
mapping using individual peptides, essentially as we have previously reported
(Barouch et al., 2010). Epitope-specific CD8+ and CD4+ T lymphocyte re-
sponses were determined by cell depletion studies.
Statistical Analyses and Immunologic Correlates
Protection against acquisition of infection was analyzed using Cox propor-
tional hazard models based on the exact partial likelihood for discrete time.
The number of challenges was used as a discrete time scale. The hazard ratios
with 95% confidence intervals (CI) for the per-exposure relative reductions of
acquisition risk were calculated for the Ad/MVA and Ad/Ad groups as
compared to the control group (Hudgens and Gilbert, 2009; Hudgens et al.,
2009). Absolute protection against acquisition of infection after 1, 3, and 6
challenges was quantitated as the percentage of uninfected animals asCell 155, 531–539, October 24, 2013 ª2013 Elsevier Inc. 537
compared to the control group. Mortality at 250 days following challenge in the
vaccine groups was compared to the control group by Fisher’s exact tests.
Analyses of virologic and immunologic data were performed using Wilcoxon
rank-sum tests. For these tests, p < 0.05 was considered significant. Immuno-
logic correlates were evaluated by Spearman rank-correlation tests, and p <
0.001 was considered significant to adjust for multiple (47) comparisons.
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